RT Journal Article
SR Electronic
T1 Shedding of Infectious SARS-CoV-2 Despite Vaccination
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.31.21261387
DO 10.1101/2021.07.31.21261387
A1 Kasen K. Riemersma
A1 Brittany E. Grogan
A1 Amanda Kita-Yarbro
A1 Peter J. Halfmann
A1 Hannah E. Segaloff
A1 Anna Kocharian
A1 Kelsey R. Florek
A1 Ryan Westergaard
A1 Allen Bateman
A1 Gunnar E. Jeppson
A1 Yoshihiro Kawaoka
A1 David H. O’Connor
A1 Thomas C. Friedrich
A1 Katarina M. Grande
YR 2021
UL http://medrxiv.org/content/early/2021/08/24/2021.07.31.21261387.abstract
AB The SARS-CoV-2 Delta variant might cause high viral loads, is highly transmissible, and contains mutations that confer partial immune escape 1,2. Outbreak investigations suggest that vaccinated persons can spread Delta 3,4. We compared RT-PCR cycle threshold (Ct) data from 699 swab specimens collected in Wisconsin 29 June through 31 July 2021 and tested with a qualitative assay by a single contract laboratory. Specimens came from residents of 36 counties, most in southern and southeastern Wisconsin, and 81% of cases were not associated with an outbreak. During this time, estimated prevalence of Delta variants in Wisconsin increased from 69% to over 95%. Vaccination status was determined via self-reporting and state immunization records (Supplemental Figure 1).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Centers for Disease Control and Prevention contracts 75D30120C09870 and 75D30121C11060 to D.H.O and T.C.F. The authors are also members of the Upper Midwest Regional Accelerator for Genomic Surveillance funded by the Rockefeller Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The University of Wisconsin-Madison IRB office has confirmed that this project qualifies as public health surveillance activities as defined in the Common Rule, 45 CFR 46.102(l)(2). As such, the project is not deemed to be research regulated under the Common Rule and therefore, does not require University of Wisconsin-Madison IRB review and oversight. The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the Centers for Disease Control and Prevention or the institutions with which the authors are affiliated.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData and processing workflows are available at https://go.wisc.edu/p22l16. To protect potentially personally identifiable information, the publicly available dataset contains only PCR Ct values, vaccine status, symptom status, culture status, and days from symptom onset to testing for each specimen. https://go.wisc.edu/p22l16